
|Articles|May 1, 2004
Medicare to cover PDT for select AMD patients
Washington, DC-The Centers for Medicare and Medicaid Services has begun to cover ocular photodynamic therapy (PDT) with verteporfin to treat select patients with subfoveal occult, but no classic choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and subfoveal minimally classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5



























